Search results for " biopharmaceuticals"
Article
Introducing Supor Prime Filters: A Filtration Solution for High-Concentration Therapies
As you may already know, many biopharmaceutical manufacturers are producing drugs at higher concentrations. This trend is mainly driven by the demand for subcutaneous drugs that are self-admin…
Article
A Closer Look at Affinity Ligands
Affinity ligands play an exciting role in the ever-growing sphere of downstream processing. In speaking with BioPharm International®, Phillip Elliott, PhD, associate director of Process Development,…
Article
Moving Biosimilars Forward in a Hesitant Market
The biosimilars landscape is growing as market factors, such as pricing pressure, advanced bioprocessing and analytical technologies, and upcoming patent expirations for innovator biologics dr…
Article
Video: The solution to smarter column packing
Packing modern chromatography resins at large scale requires a column capable of axial compression to ensure stable, reproducible packed beds. AxiChrom™ columns are low-pressure, axial compressi…
Article
Discovering the unknown: How does in silico process development change PD scientists’ work?
In silico process development for chromatography is a paradigm-shifting approach that redefines the routine work of process development scientists. But what does it actually mean to perfor…
Article
Paring Down Impurities in Downstream Processing
Myriad choices confront manufacturers before they even consider optimizing downstream processes. Each decision directly influences what final options will be available on arriving at the final…
Article
A scalable single-use two-step plasmid purification process
The current global demand for biopharmaceuticals is over USD 300 billion, with an estimated growth of ≥ 12% annually. While MAb processes have become much more efficient, production of mRN…
Article
Democratizing GMP Manufacturing for the New Therapeutic Pipeline
PharmTech Europe discusses technology that enables the “democratization” of mRNA manufacturing with Scott Ripley, general manager, Nucleic Acid Therapeutics and Precision Nanosystems, Cytiva, …
Article
Report from the 6th International HTPD Conference
The biggest challenge is still the people and Quantitative Structure-Activity Relationship (QSAR) plus mechanistic modeling were two key take-home messages from the 6th International conference devote…
Webcast
Biotech Makers: Solving challenges in process development of a diversifying antibody pipeline
The therapeutic pipeline for antibodies continues to diversify into new modalities including bi-specific, tri-specific, antibody fragments and domain antibodies which bring new challenges to process…